Intervention Review

You have free access to this content

Rituximab for relapsing-remitting multiple sclerosis

  1. Dian He1,
  2. Rui Guo2,
  3. Fubo Zhang3,
  4. Chao Zhang4,
  5. Shuai Dong2,
  6. Hongyu Zhou5,*

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 6 DEC 2013

Assessed as up-to-date: 9 AUG 2013

DOI: 10.1002/14651858.CD009130.pub3


How to Cite

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD009130. DOI: 10.1002/14651858.CD009130.pub3.

Author Information

  1. 1

    Affiliated Hospital of Guiyang Medical College, Department of Neurology, Guiyang, Guizhou Province, China

  2. 2

    Jinan No. 6 People's Hospital, Department of Neurology, Jinan, Shandong Province, China

  3. 3

    Cangzhou City Cemtral Hospital, Department of Neurology, Cangzhou, Hebei Province, China

  4. 4

    Jinan No. 6 People's Hospital, Department of Internal Medicine, Jinan, Shandong Province, China

  5. 5

    West China Hospital, Sichuan University, Department of Neurology, Chengdu, Sichuan, China

*Hongyu Zhou, Department of Neurology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China. Hyzhou98@yahoo.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 6 DEC 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Hauser 2008 {published data only}
  • Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine 2008;358(7):676-88.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Bar-Or 2008 {published data only}
  • Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Annals of Neurology 2008;63(6):803.
Naismith 2010 {published data only}
  • Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology 2010;74(23):1860-7.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
NCT01569451 {published data only}
  • A Double Blinded, Placebo Controlled, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis. Ongoing study February 2012.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
Barr 2012
  • Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. Journal of Experimental Medicine 2012;209(5):1001-10.
Cancer Therapy Evaluation Program 2006
  • National Cancer Institute. The NCI Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (Accessed 28 October 2013).
Castillo-Trivino 2013
  • Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 2013;8(7):e66308.
Cella 1996
Confavreux 2006
Cross 2006
  • Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. Journal of Neuroimmunology 2006;180(1-2):63-70.
Di Gaetano 2003
  • Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. Journal of Immunology 2003;171(3):1581-7.
Duddy 2006
  • Duddy M, Bar-Or A. B-cells in multiple sclerosis. The International MS Journal 2006;13:84-90.
FDA 2013
  • U.S. Food, Drug Administration. Rituxan full prescribing information 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103705s5414lbl.pdf (Accessed 28 October 2013).
Filippini 2013
  • Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD008933.pub2]
Fischer 1999
  • Fischer JS, La Rocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Multiple Sclerosis 1999;5(4):251-9.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org.
Karampampa 2012a
  • Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Multiple Sclerosis 2012;18(2 Suppl):7-15.
Karampampa 2012b
  • Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. Journal of Population Therapeutics and Clinical Pharmacology 2012;19(1):11-25.
Kurtzke 1983
Lublin 1996
  • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
Martin 2009
  • Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Archives of Neurology 2009;66(8):1016-20.
McDonald 2001
Oleen-Burkey 2012
Piccio 2010
  • Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Archives of Neurology 2010;67(6):707-14.
Polman 2005
Polman 2011
Poser 1983
Reff 1994
  • Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435-45.
Review Manager 2013
  • The Nordic Cochrane Centre, The CochraneCollaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The CochraneCollaboration, 2013.
Taupin 2011
Vickrey 1995
Ware 1992
Waubant 2008
  • Waubant E. Spotlight on anti-CD20. The International MS Journal 2008;15(1):19-25.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
  5. References to other published versions of this review
He 2011
  • He D, Zhou H, Han W, Zhang S. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD009130.pub2]